Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing

Abstract Adoptive immunotherapy with engineered T cells, especially chimeric antigen receptor (CAR) T cells, has revolutionized the treatment of leukemia, lymphoma, and multiple myeloma. However, the high production costs of CAR-T therapy severely limit patient access. To address this challenge, we developed T-pureTM, a proprietary bispecific antibody cocktail for isolating T cells from human blood through negative selection. The Bi-specific antibody cocktail selectively links red blood cells (RBCs) to key marker antigens on non-target cells, such as B cell, NK cell, Monocytes, and granulocytes, allowing easy and cost-effective separation using Ficoll density gradient centrifugation. By isolating T cells without engaging their surface receptors, this approach avoids inadvertent activation of isolated T cells, while also preserving cell types like γδ T cells, which show promise for their anti-tumor potential. Additionally, the depletion process efficiently removes CD19-positive cancer cells and can be tailored to eliminate T cell subpopulations like T regulatory (T-reg) cells that could compromise CAR-T efficacy in clinical application. This versatile antibody cocktail can also be adapted to isolate other cell types, such as NK cells, B cells, and monocytes for various biomedical applications. Designed for cost-effective clinical manufacturing, our GMP grade T-pure reagents are commercially available to academic and industry partners for preclinical and clinical applications. This work highlights the ongoing innovation in CAR-T manufacturing and the potential for optimizing cell selection protocols to enhance efficacy and lower the cost of cell therapies. Citation Format: Ying Xiong, Yanping Xie, Ann Wang, Victor Bass, Matt Addington-hall, Oxana Slessareva, Yang Liu, Tony Luo, Ibeawuchi Oparaocha, Kathy Schonely, Kara Anlauf, Megan Forrest, Jacqueline Schaeffer, Shashi Koduru, Andrew Worden, Mike Kadan, Boro Dropulic, Zhongyu Zhu. T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6095.